Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Overview

This study evaluates the efficacy of the addition of prednisolone to conventional initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in reducing coronary artery lesion in children with Kawasaki disease (KD) .

Full Title of Study: “Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease: A Multicentre Randomised Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: September 2024

Detailed Description

This is a multicenter, open-label, blind-endpoints, randomized controlled trial at more than 10 hospitals in China. The investigators enrolled KD children diagnosed within 10 days of onset. Participants will be randomly assigned in a 1:1 ratio to the control group (receiving 2g/kg IVIG and 30 mg/kg aspirin) or the intervention group (receiving 2 g/kg IVIG, 30 mg/kg aspirin and additional 2 mg/kg prednisolone). Baseline characteristics of each participant will be collected, including sex, age of onset, height, body weight, subtype of KD, fever days before initial IVIG, echocardiographic findings at enrolment, and a series of pre-IVIG laboratory tests. Two-dimensional echocardiography will be performed at admission, 2 weeks, 1 month, 3 months, 6 months,and 12 months after onset of KD to assess the coronary artery lesions.

Interventions

  • Drug: IVIG
    • IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
  • Drug: Aspirin
    • Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
  • Drug: Prednisolone
    • Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.

Arms, Groups and Cohorts

  • Active Comparator: the standard group
    • IVIG 2g/kg once, given within 12 to 24 hours; Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
  • Experimental: the standard+prednisolone group
    • IVIG 2g/kg once, given within 12 to 24 hours; Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness. Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of coronary artery lesions(CAL) at one month of illness
    • Time Frame: at one month of illness
    • Two-dimensional echocardiography will be performed to evaluate CAL at 1 month of illness. The measurement of each patient included the diameter of the left main coronary artery (LMCA), the left anterior descending artery (LAD), the left circumflex coronary artery (LCX), and the proximal and middle segments of the right coronary artery (RCA). Z score of each coronary artery will be calculated(Journal of the American Society of Echocardiography, 2011, 24(1).). CAL is defined as z≥2of any coronary artery of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.

Secondary Measures

  • Percentage of the need for additional treatment
    • Time Frame: from admission to discharge (about 2 weeks of illness)
    • Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. Participants who have recurrent or persistent fever (axillary temperature ≥37.5°C or rectal temperature ≥38°C) after 36 hours of completion of initial IVIG infusion will be given additional treatment.
  • Duration of fever (hours) after initiation of initial IVIG infusion
    • Time Frame: from initiation of initial IVIG infusion to the first record of being afebrile(defined as an axillary temperature <37.5 for more than 24 hours)
    • Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. Participants with an axillary temperature <37.5℃ (or rectal temperature <38℃) for more than 24 hours are considered afebrile. Record the time of the initiation of IVIG infusion and the time of the body temperature first becoming normal.
  • Changes in z scores of LMCA throughout the study period
    • Time Frame: from admission to 12 months of illness
    • This is a repeated measurement. The internal diameter of LMCA will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).
  • Changes in z scores of LAD throughout the study period
    • Time Frame: from admission to 12 months of illness
    • This is a repeated measurement. The internal diameter of LAD will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).
  • Changes in z scores of LCX throughout the study period
    • Time Frame: from admission to 12 months of illness
    • This is a repeated measurement. The internal diameter of LCX will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).
  • Changes in z scores of the proximal segment of RCA throughout the study period
    • Time Frame: from admission to 12 months of illness
    • This is a repeated measurement. The internal diameter of the proximal segment of RCA will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).
  • Changes in z scores of the middle segment of RCA throughout the study period
    • Time Frame: from admission to 12 months of illness
    • This is a repeated measurement. The internal diameter of the middle segment of RCA will be measured by echocardiography at six time points: at enrolment, at 2 weeks, 1 month, 3 months, 6 months and 12 months of illness. Z score will be calculated based on the height, weight and coronary artery diameter(Journal of the American Society of Echocardiography, 2011, 24(1).).
  • Change in serum C-reactive protein (CRP) concentration
    • Time Frame: from admission to 72 hours after completion of initial IVIG infusion
    • CRP level is measured before initial IVIG infusion and 72 hours after completion of initial IVIG infusion.
  • Number of patients with serious adverse events
    • Time Frame: from admission to 3 months of illness
    • This is a composite outcome, including death, hypertension, severe infection, allergic reactions, heart failure, thrombosis, etc.

Participating in This Clinical Trial

Inclusion Criteria

  • Meeting diagnostic criteria for Kawasaki disease (KD) released by American Heart Association (AHA) in 2017 – Diagnosed before the tenth day of illness (with the first day of illness defined as the first day of fever) – Not treated with IVIG yet – Age ≥1 month Exclusion Criteria:

  • Z score of any coronary artery before initial treatment ≥10 – Receiving steroids or other immunosuppressive agents in the previous 30 days – With a previous history of KD – Afebrile before enrolment – With suspected infectious diseases including sepsis, septic meningitis, peritonitis, bacterial pneumonia, varicella and influenza – With serious immune diseases such as immunodeficiency or chromosomal abnormalities

Gender Eligibility: All

Minimum Age: 1 Month

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Children’s Hospital of Fudan University
  • Collaborator
    • Jiangxi Province Children’s Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Fang Liu, MD., Study Director, Children’s Hospital of Fudan University
  • Overall Contact(s)
    • Fang Liu, MD., +86 021-64932800, liufang@fudan.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.